Location

LSU Health Sciences Center - New Orleans

Event Website

https://www.medschool.lsuhsc.edu/genetics/2023_medical_student_research_poster_symposium.aspx

Presentation Date

23-10-2023 8:30 AM

Description

OBJECTIVES: Our goal is to understand the impact of age and educational level in cognitive impairment assessments of patients with Parkinson’s Disease in the Greater New Orleans area.

INTRODUCTION: Parkinson’s Disease (PD) is a neurodegenerative brain disorder found to be age-related, affecting 3% of individuals aged 65 and up to 5% of individuals over 85 years of age (Cerri et al, 2019). We hypothesize that individuals 65 years of age or older and those having 12 years of education or less diagnosed with PD will result in a lower cognitive impairment than seen in comparable groups.

METHODS: Participates diagnosed with Parkinson’s Disease (PD) were enrolled in our study to assess cognitive impairment. They underwent cognitive assessment using the Montreal Cognitive Assessment (MoCA) and the Symbol Digit Modalities Test (SDMT). Healthy controls were also enrolled in our study and underwent the same cognitive impairment assessments using the MoCA and SDMT

Comments

Mentor: Dr. Deidre Devier LSUHSC, Louisiana State University Health Network Clinics (LSUHN)

Share

COinS
 
Oct 23rd, 8:30 AM

Effects Of Age and Educational Level in Cognitive Impairment Assessment in Parkinson’s Disease

LSU Health Sciences Center - New Orleans

OBJECTIVES: Our goal is to understand the impact of age and educational level in cognitive impairment assessments of patients with Parkinson’s Disease in the Greater New Orleans area.

INTRODUCTION: Parkinson’s Disease (PD) is a neurodegenerative brain disorder found to be age-related, affecting 3% of individuals aged 65 and up to 5% of individuals over 85 years of age (Cerri et al, 2019). We hypothesize that individuals 65 years of age or older and those having 12 years of education or less diagnosed with PD will result in a lower cognitive impairment than seen in comparable groups.

METHODS: Participates diagnosed with Parkinson’s Disease (PD) were enrolled in our study to assess cognitive impairment. They underwent cognitive assessment using the Montreal Cognitive Assessment (MoCA) and the Symbol Digit Modalities Test (SDMT). Healthy controls were also enrolled in our study and underwent the same cognitive impairment assessments using the MoCA and SDMT

https://digitalscholar.lsuhsc.edu/sommrd/2023MSRD/Posters/41